Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Recombinant protein therapeutics—success rates, market trends and values to 2010

Despite entering its maturation phase, the recombinant protein sector will continue to drive the growth of medical biotechnology over the next six years.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: US approval success rates for rDNA therapeutics in two periods.

Bob Crimi

Figure 2: Phase transition probabilities by therapeutic category for rDNA products entering clinical study during 1990–1997.

Bob Crimi

Figure 3: Market growth generated by three business waves and recorded between 2001 and 2003.

Bob Crimi

Figure 4: Therapeutic market segmentation from 2001 to 2003.

Bob Crimi

Figure 5: Distribution of market subsegments generated by the industry's leading recombinant protein brands within the 57% total market share in 2010.

Bob Crimi

Figure 6: Market growth from 2004 to 2010.

Bob Crimi


  1. 1

    Reichert, J.M. & Paquette, C. Therapeutic recombinant proteins: trends in US approvals 1982-2002. Curr. Opin. Mol. Ther. 5, 139–147 (2003).

    CAS  PubMed  Google Scholar 

  2. 2

    Reichert, J.M. Biopharmaceutical approvals in the US. Reg. Affairs J. Pharma 15, 491–497 (2004).

    Google Scholar 

  3. 3

    Reichert, J.M. & Pavlou, A. Monoclonal antibodies market. Nat. Rev. Drug Discovery 3, 383–384 (2004).

    CAS  Article  Google Scholar 

  4. 4

    Reichert, J.M. Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr. Opin. Mol. Ther. 4: 110–118 (2002).

    CAS  PubMed  Google Scholar 

  5. 5

    Reichert, J.M. Monoclonal antibodies in the clinic. Nat. Biotechnol. 19, 819–822 (2001).

    CAS  Article  Google Scholar 

Download references

Author information



Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pavlou, A., Reichert, J. Recombinant protein therapeutics—success rates, market trends and values to 2010. Nat Biotechnol 22, 1513–1519 (2004).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing